{{Short description|South African and American doctor (born 1952)}} {{Promotional|date=October 2025}} {{use mdy dates|date=February 2020}} {{CS1 config|mode=cs1}} {{Infobox person | name = Patrick Soon-Shiong | image = Dr Patrick Soon-Shiong (14212355607) cropped.jpg | caption = Soon-Shiong in 2014 | birth_date = {{birth date and age|1952|7|29}} | birth_place = Port Elizabeth, Union of South Africa | death_date = | death_place = | known_for = Inventor of Abraxane<br />Developer of transplant techniques for pancreatic islets | education = University of the Witwatersrand (MBBCh, MD) <br /> University of British Columbia (MSc) <br /><!-- University of the Witwatersrand (MD)--> | occupation = {{hlist|Businessman|investor|medical researcher| transplant surgeon}} | citizenship = South Africa<br />United States<ref name=congress/> | title = Founder & CEO Nantworks LLC<br /> Owner of ''Los Angeles Times''<br /> Minority owner of Los Angeles Lakers | party = | spouse = Michele B. Chan | children = 2, including Nika | module = {{infobox Chinese |child=yes |t=黃馨祥 |s=黄馨祥 |p=Huáng Xīnxiáng |j=Wong4 Hing1 Coeng4 }} }}
'''Patrick Soon-Shiong''' ({{Lang-zh|t=|s=|c=黄馨祥}}; born July 29, 1952) is a South African and American <!-- Soon-Shiong is a dual citizen of South Africa and the United States. --> businessman, researcher and surgeon who invented Abraxane, a drug used for lung, breast, and pancreatic cancer. He has been owner and executive chairman of the ''Los Angeles Times'' since 2018.<ref name="Tronc" />
Soon-Shiong received FDA approval for a new class of immunotherapy drug called Anktiva in non-muscle invasive bladder cancer in 2024. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups;<ref name="Forbes">{{cite journal | author = Moukheiber, Zina | date = 2011-11-10 | title=Billionaire Patrick Soon-Shiong Wants To Remake The U.S. Health Care System | journal = Forbes | format = online | url = https://www.forbes.com/sites/zinamoukheiber/2011/11/10/billionaire-patrick-soon-shiong-wants-to-remake-the-u-s-health-care-system/ | access-date=2016-11-20}}</ref> an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College.<ref name="AcademicBios">Biographies providing these details include {{Cite web |url=http://www.ita.ucla.edu/people/advisory-board/patrick-soon-shiong |title=Patrick Soon-Shiong, M.D. |access-date=3 April 2015 |website=UCLA Engineering |publisher=UCLA |archive-url=https://www.webcitation.org/6XVlVCGkE?url=http://www.ita.ucla.edu/people/advisory-board/patrick-soon-shiong |archive-date=3 April 2015}}, {{Cite web |author=Soon-Shiong, P. |year=2015 |title=Patrick Soon Shiong |url=http://www.ita.ucla.edu/patrick-soon-shiong/ |website=Institute for Technology Advancement |access-date=2015-11-05 |publisher=UCLA Engineering |archive-url=https://web.archive.org/web/20151105001918/http://www.ita.ucla.edu/patrick-soon-shiong/ |archive-date=2015-11-05 |url-status=dead}}, and {{Cite web |author=Soon-Shiong, P. |date=2008 |url=http://www1.cnsi.ucla.edu/INC5/cv/SoonShiongPatrickCV.pdf |title=Curriculum Vitae. Patrick Soon-Shiong, M.D., MSc, FRCS(C), FACS |access-date=2015-11-04 |website=INC5 |publisher=California NanoSystems Institute}}</ref><ref>Biographies providing these details include {{cite web | url= http://nantkwest.com/project/patrick-soon-shiong-m-d-frcs-c-facs/ | title= Patrick Soon-Shiong, M.D., FRCS (C), FACS | author= Soon-Shiong, P. | date= 2016 | work= NantKwest.com | access-date= 2016-11-21 | archive-date= November 22, 2016 | archive-url= https://web.archive.org/web/20161122072546/http://nantkwest.com/project/patrick-soon-shiong-m-d-frcs-c-facs/ | url-status= dead }}</ref><ref name="labusinessjournal">{{Cite web|url=https://labusinessjournal.com/news/2017/aug/10/la-500-patrick-soon-shiong/|title=LA 500: Patrick Soon-Shiong|website=Los Angeles Business Journal|date=August 10, 2017 }}</ref> He is currently Executive Chairman, Global Chief Medical & Technology Officer at ImmunityBio.
Soon-Shiong is the chairman of Chan Soon-Shiong Family Foundation, a non-profit foundation. He has been a minority owner of the Los Angeles Lakers since 2010.<ref name="Tronc">{{cite press release|author=<!--Staff writer(s); no by-line.-->|date=June 18, 2018|title=tronc, Inc. Announces Closing of the Los Angeles Times and The San Diego Union-Tribune Sale|location=Chicago|publisher=Tronc|url=http://investor.tronc.com/phoenix.zhtml?c=254385&p=irol-newsArticle&ID=2355030 |access-date=June 18, 2018}}</ref> Soon-Shiong's net worth is estimated at US$16.6 billion as of 2026 according to the ''Bloomberg Billionaires Index'' and ''Forbes''.<ref>{{Cite web |title=Patrick Soon-Shiong |url=https://www.forbes.com/profile/patrick-soon-shiong/ |access-date=2026-02-18 |website=Forbes }}</ref> He has been called the richest man in Los Angeles and one of the wealthiest doctors in the world.<ref>{{Cite magazine |last=Witt |first=Stephen |date=2021-10-25 |title=How Patrick Soon-Shiong Made His Fortune Before Buying the L.A. Times |url=https://www.newyorker.com/magazine/2021/11/01/how-patrick-soon-shiong-made-his-fortune-before-buying-the-la-times |access-date=2024-07-18 |magazine=The New Yorker |language=en-US |issn=0028-792X}}</ref>
== Early life and education == Soon-Shiong was born in Port Elizabeth in the Union of South Africa in present-day South Africa, to Chinese immigrant parents who fled China during the Japanese occupation in World War II.<ref name="whitford2013" /><ref name="gs">{{cite journal | author = GoldSea Staff | year = c. 2010 | title = Biotech Kahuna Patrick Soon-Shiong | website =GoldSea.com | url=https://goldsea.com/Text/index.php?id=10298 | access-date=2016-11-21}}</ref> His parents were Hakka originally from Meixian District in Guangdong province.<ref name="gs" /><ref name="whitford2013" /> His ancestral surname is Huang (黃).<ref name="gs" />
Soon-Shiong graduated from the University of Witwatersrand, where he was fourth in his class of 189 and received a bachelor's degree in medicine (MBBCh) at age 23.<ref name = ForbesArmstrong030610>{{Cite journal | url = https://www.forbes.com/forbes/2003/1006/126.html | title = Vindication | date = 2003-06-10 | access-date = 2015-04-13 | website = Forbes.com | last = Armstrong | first = David }}</ref> He completed his medical internship at Johannesburg's General Hospital.<ref>{{cite news | url=https://www.latimes.com/business/la-fi-soon-shiong-latimes-20180207-story.html | title=Who is Patrick Soon-Shiong? An L.A. billionaire with big ideas — and mixed achievements| newspaper=Los Angeles Times | date=2018-02-07}}</ref> He then studied at the University of British Columbia, where he earned a master's degree in surgery in 1979.<ref>{{Cite web |date=2016-05-23 |title=Who is Patrick Soon-Shiong, Tribune Publishing's new No. 2 shareholder? |url=https://www.latimes.com/business/la-fi-soon-shiong-20160523-snap-htmlstory.html |website=Los Angeles Times |language=en-US}}</ref> He also has an M.D. from University of Witwatersrand.<ref>{{cite web|url=https://open.library.ubc.ca/media/download/pdf/831/1.0094603/1| title=Fundic Inhibition of Acid Secretion and Gastrin Release (Master's Thesis)|date=October 1979|access-date=2018-05-26}}</ref> He received research awards from the American College of Surgeons, the Royal College of Physicians and Surgeons of Canada, and the American Association of Academic Surgery.<ref name=":0">{{cite web|url=https://www.wits.ac.za/alumni/news/achievers/3329/patrick_soon_shiong.html|title=Patrick Soon-Shiong – Alumni Achievers – News – News & Events – Alumni – Wits University|date=13 April 2015|url-status=bot: unknown|archive-url=https://web.archive.org/web/20150413112812/https://www.wits.ac.za/alumni/news/achievers/3329/patrick_soon_shiong.html|archive-date=13 April 2015}}</ref>
He immigrated to the United States and began surgical training at University of California, Los Angeles (UCLA), and became a board-certified surgeon in 1984.<ref>{{cite web |url=https://www.absurgery.org/reports.jsp?jr=surg_cert_status&candidate=039059 |title=American Board of Surgery |access-date=February 11, 2018 |archive-date=February 12, 2018 |archive-url=https://web.archive.org/web/20180212005254/https://www.absurgery.org/reports.jsp?jr=surg_cert_status&candidate=039059 |url-status=dead }}</ref> Soon-Shiong is a Fellow of the Royal College of Surgeons (Canada) and a Fellow of the American College of Surgeons.<ref name=":0" /><ref name=AcademicBios/> He is a United States citizen.{{refn|group="Note"|The earliest date of US citizenship found in sources goes back to 2007.<ref name=ForbesCitizen2007/>}}<ref name=congress>{{Cite web| title=Hearing on "Progress and Present Challenges on COVID-19 in Africa" by Dr. Patrick Soon-Shiong | url=https://www.congress.gov/117/meeting/house/114568/witnesses/HHRG-117-FA16-Bio-Soon-ShiongP-20220331.pdf | archive-url=https://web.archive.org/web/20230804054552/https://www.congress.gov/117/meeting/house/114568/witnesses/HHRG-117-FA16-Bio-Soon-ShiongP-20220331.pdf | archive-date=2023-08-04}}</ref><ref name=ForbesCitizen2007>{{Cite web |title=#249 Patrick Soon-Shiong - Forbes.com |url=https://images.forbes.com/lists/2007/10/07billionaires_Patrick-Soon-Shiong_VI4N.html |access-date=2025-07-29 |website=images.forbes.com}}</ref>
== Career == Soon-Shiong served on the faculty of the UCLA Medical School from 1983 until 1991<ref>{{cite press release | url=http://newsroom.ucla.edu/releases/ucla-wireless-health-institute-92756 | title=UCLA names Soon-Shiong executive director of Wireless Health Institute |first=Wileen Wong | last=Kromhout | date=May 21, 2009 | publisher=UCLA}}</ref><ref name=AcademicBios/> as a transplant surgeon.<ref name="whitford2013">{{Cite news | title = Whitford, David|author = Whitford, David [with Jones, Marty] | date = 2013-12-09 |journal = Fortune | format = print and online | pages = 138–140 | url = http://fortune.com/2013/11/21/patrick-soon-shiong/ | access-date=2016-11-20 }}</ref> Between 1984 and 1987, he served as an associate investigator at the Center for Ulcer Research and Education.<ref name=AcademicBios/> Soon-Shiong performed the first whole-pancreas transplant done at UCLA.<ref name=UMagUCLA15>{{cite magazine | last=Light | first=Leti McNeill | date=11 May 2015 | title=Visions of progress and courage | journal=U Magazine | volume=35 | number=2 | publication-place=Los Angeles | publisher=UCLA | pages=42 | url=http://magazine.uclahealth.org/workfiles/UMagazine_Spring_2015.pdf#page=44 | access-date=2016-11-20 | url-status=dead | archive-url=https://web.archive.org/web/20150911073242/http://magazine.uclahealth.org/workfiles/UMagazine_Spring_2015.pdf#page=44 | archive-date=2015-09-11}}</ref><ref>Whole pancreas transplantation began as a part of multi-organ transplants, in the mid-to-late 1960s, at the University of Minnesota. See {{cite journal |author1=Squifflet, J.P. |author2=Gruessner, R.W. |author3=Sutherland, D.E. | date = 2008 | title = The History of Pancreas Transplantation: Past, Present and Future | journal = Acta Chir. Belg. | volume = 108 | issue = 3, May–June | pages = 367–378 |doi=10.1080/00015458.2008.11680243 | quote = The first attempt to cure type 1 diabetes by pancreas transplantation was done at the University of Minnesota, in Minneapolis, on December 17, 1966… [This] opened the door to a period, between the mid-[1970s] to mid-[1980s] where only segmental pancreatic grafts were used... In the late [1970s] – early [1980s], three major events… boosted the development of pancreas transplantation… [At] the Spitzingsee meetings, participants had the idea to renew the urinary drainage technique of the exocrine secretion of the pancreatic graft with segmental graft and eventually with whole pancreaticoduodenal transplant. That was clinically achieved during the mid-[1980s] and remained the mainstay technique during the next decade. In parallel, the Swedish group developed the whole pancreas transplantation technique with enteric diversion. It was the onset of the whole pancreas reign. The enthusiasm for the technique was moderated in its early phase due to the rapid development of liver transplantation and the need for sharing vascular structures between both organs, liver and pancreas. During the modern era of immunosuppression, the whole pancreas transplantation technique with enteric diversion became the gold standard… [for SPK, PAK, PTA]. | pmid=18710120|s2cid=25795725 }}</ref> He developed and first performed the experimental Type 1 diabetes-treatment known as encapsulated-human-islet transplant, and the "first pig-to-man islet-cell transplant in diabetic patients."<ref name=UMagUCLA15/> After a period in private industry, he returned to UCLA in 2009, serving as a professor of microbiology, immunology, molecular genetics, and bioengineering. Soon-Shiong was a visiting professor at Imperial College, London, in 2011.<ref name=UCLAcommence>{{cite web|url=https://engineering.ucla.edu/visionary-healthcare-entrepreneur-and-philanthropist-dr-patrick-soon-shiong-to-speak-at-ucla-engineering-commencement/|archive-url=https://web.archive.org/web/20120522073412/http://www.engineer.ucla.edu/newsroom/featured-news/archive/2011/visionary-healthcare-entrepreneur-and-philanthropist-dr.-patrick-soon-shiong-to-speak-at-ucla-engineering-commencement|title=Visionary healthcare entrepreneur and philanthropist, Dr. Patrick Soon-Shiong, to speak at UCLA Engineering commencement – UCLA Engineering|archive-date=22 May 2012|date=May 6, 2011|url-status=dead}}</ref>
In 2010, in partnership with Arizona State University and the University of Arizona, Soon-Shiong established the Healthcare Transformation Institute (HTI).<ref>{{cite news |title=Message from the CEO and President |url=http://www.healthcaretransformationinstitute.org/page/message-ceo-and-president |first=Patrick |last=Soon-Shiong |date=Sep 8, 2011 |access-date=9 April 2012 |archive-date=April 25, 2012 |archive-url=https://web.archive.org/web/20120425070448/http://www.healthcaretransformationinstitute.org/page/message-ceo-and-president |url-status=dead }}</ref> HTI's mission is to promote a shift in health care in the United States by better integrating the three now separate domains of medical science, health delivery, and healthcare finance.<ref name="Forbes" /><ref>{{cite news|title='Patrick Soon-Shiong Talks With ASU's Michal Crow about the Imminent, Hoped-For Healthcare Revolution' |url=http://zocalopublicsquare.org/full_video.php?event_id=552 |author1=Crow, Patrick |author2=Soon-Shiong, Pattrick | date=2012-09-05}}{{dead link|date=November 2016}}</ref>
In early 2016, Soon-Shiong launched the National Immunotherapy Coalition to encourage rival pharmaceutical companies to work together to test combinations of cancer-fighting drugs.<ref>{{Cite web|url=https://www.statnews.com/2016/01/11/cancer-coalition-combination-drugs/|title=Rival drug firms team up to test new cancer treatment approach|date=2016-01-11|website=STAT|access-date=2017-04-13}}</ref> He also met with Joe Biden in 2015 to discuss approaches to fighting cancer, including conducting genomic sequencing of 100,000 patients to create a large database of potential genetic factors.<ref>{{Cite news|url=https://www.nytimes.com/2015/11/02/us/politics/if-cancer-becomes-bidens-cause-a-bold-but-polarizing-doctor-is-on-call.html|title=If Cancer Becomes Biden's Cause, a Bold but Polarizing Doctor Is On Call|last=Baker|first=Peter|date=2015-11-01|work=The New York Times|access-date=2017-04-13|issn=0362-4331}}</ref>
In January 2017, as announced by press secretary Sean Spicer, then President-elect Donald Trump met with Soon-Shiong at Trump's Bedminster, New Jersey, estate to discuss national medical priorities.<ref>{{cite news| url=https://www.washingtonpost.com/news/post-politics/wp/2017/01/10/the-full-transcript-from-the-trump-transition-teams-tuesday-call-to-reporters-6/ |title=The full transcript from the Trump transition team's Tuesday call to reporters |newspaper=The Washington Post |date=January 10, 2017|access-date=February 7, 2018}}</ref> According to Politico, Soon-Shiong was seeking a cabinet position.<ref name=":1">{{Cite news |last=Tahir |first=Darius |date=April 9, 2017 |title=How Washington's favorite cancer fighter helps himself |url=https://www.politico.com/story/2017/04/patrick-soon-shiong-taxes-nanthealth-foundation-236728 |access-date=October 24, 2024 |work=Politico}}</ref> In May 2017, Soon-Shiong was appointed by House Speaker Paul Ryan to the Health Information Technology Advisory Committee, a committee established by the 21st Century Cures Act.<ref>{{cite news|url=https://www.politico.com/story/2017/05/30/paul-ryan-cancer-doctor-238961|title=Ryan appoints controversial cancer doctor to HHS committee|date=2017-05-30|work=Politico}}</ref>
In 2017, Soon-Shiong and his wife were invited by the Smithsonian to be part of the permanent exhibit "Many Voices, One Nation" in the National Museum of American History in Washington DC.<ref>{{Cite web|last=Anderson|first=Maria|date=May 9, 2017|title="Tracing American Journeys" Chronicles Experiences of 17 Immigrant Entrepreneurs|url=https://insider.si.edu/2017/05/tracing-american-journeys-chronicles-experiences-of-17-immigrant-entrepreneurs/|access-date=Oct 8, 2021|website=Smithsonian Insider}}</ref>
By summer 2021, ImmunityBio had developed a T cell-inducing universal COVID-19 vaccine booster shot that had reached Phase III trials in his native South Africa, with a stated goal of completely blocking transmission and stemming an endemic tide of COVID-19 variants.<ref>{{cite news|last1=Swisher|first1=Kara|date=August 12, 2021|title=Should We Worry As Billionaires Buy Up Newspapers?|work=New York Times|url=https://www.nytimes.com/2021/08/12/opinion/sway-kara-swisher-patrick-soon-shiong.html?showTranscript=1|access-date=August 12, 2021|archive-url=https://web.archive.org/web/20210813003531/https://www.nytimes.com/2021/08/12/opinion/sway-kara-swisher-patrick-soon-shiong.html?showTranscript=1|archive-date=August 13, 2021}}</ref> In December 2021, Soon-Shiong shared pre-clinical results of giving two different vaccine platforms (heterologous) and showed beneficial T cell levels using an adenovirus and mRNA technology.<ref>{{Cite web|date=2021-12-05|title=Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination|url=https://www.news-medical.net/news/20211205/Preclinical-data-shows-enhanced-T-cell-responses-neutralization-of-SARS-CoV-2-variants-with-ImmunityBio-heterologous-vaccination.aspx|access-date=2022-02-19|website=News-Medical.net}}</ref>
In September 2021, Soon-Shiong and President Cyril Ramaphosa of South Africa announced via a virtual press conference a new venture called NantSA with NantWorks to expand the capability of vaccine development for Sub-Saharan Africa.<ref>{{cite AV media | people=Seale, Tyrone Alexander (Host); Cyril Ramaphosa; Patrick Soon-Shiong; Glenda Gray; Blade Nzimande; Ebrahim Patel; Eugene Cloete; Mamokgethe Phakeng; Zeblon Z. Vilakazi; Tulio de Oliveira; Phil Mjwara (Guests) | title=President Cyril Ramaphosa attends the launch announcement by Dr Soon-Shiong of NantAfrica COVID-19 | date=September 23, 2021 | publisher=Government of South Africa | via=YouTube | url=https://www.youtube.com/watch?v=Qz_LnttDnvQ | language=en | access-date=2021-10-08}}</ref> NantWorks has signed a collaboration agreement with the South African government's Council for Scientific and Industrial Research, the South African Medical Research Council (SAMRC) and the Centre for Epidemic Response and Innovation.<ref>{{Cite news|last=Sguazzin|first=Antony|date=September 24, 2021|title=L.A. Times owner plans South Africa vaccine plant|work=Los Angeles Times|url=https://www.latimes.com/business/story/2021-09-24/l-a-times-owner-soon-shiong-plans-south-africa-vaccine-plant|access-date=Oct 8, 2021}}</ref>
In February 2022, Soon-Shiong announced results from ImmunityBio regarding a clinical trial in non-muscle invasive bladder cancer (NMIBC) with a 24.1 median duration and 71% complete remission.<ref>{{Cite web|title=ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New 'Magnitude of Benefit' in Patients with BCG Unresponsive Bladder Cancer|url=https://finance.yahoo.com/news/immunitybio-announces-over-24-months-221700126.html|access-date=2022-02-19|website=finance.yahoo.com|language=en-US}}</ref> The drug was approved by the FDA in April 2024 under the name nogapendekin alfa inbakicept-pmln "ANKTIVA".<ref>{{Cite journal |last=Research |first=Center for Drug Evaluation and |date=2024-08-09 |title=FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer |journal=FDA |language=en}}</ref>
Furthering cancer related studies, Soon-Shiong and colleagues identified a consistent association between absolute lymphocyte count (ALC) and overall survival across multiple solid tumor types. Their analysis of data from the QUILT clinical trial program suggested that patients with lymphopenia (ALC <1.0 ×10³/μL) had markedly worse outcomes, and that restoration of ALC following treatment correlated with prolonged survival. To test whether lymphocyte restoration could be therapeutically induced, the group investigated nogapendekin alfa inbakicept (NAI, also known as N-803 and marketed as ANKTIVA''')''', an interleukin-15 (IL-15) superagonist designed to stimulate proliferation and activation of natural killer (NK) and CD8⁺ T cells without expanding regulatory T cells. In June 2025, the U.S. Food and Drug Administration (FDA) granted Expanded Access authorization for ANKTIVA in patients with solid tumors who had progressed after first-line therapy,<ref>{{Cite web |last= |date=2025-06-02 |title=ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors |url=https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/ |access-date=2025-10-07 |website=ImmunityBio |language=en-US}}</ref> allowing its use for the treatment of lymphopenia and immune reconstitution in this setting. The work proposed that lymphopenia itself represents a modifiable pathophysiologic state rather than a byproduct of disease or treatment, positioning immune restoration through IL-15 agonism as a potential therapeutic strategy across malignancies.
== Business career == ===Pharmaceutical, biotech, and energy=== In 1991, Soon-Shiong left UCLA to start a diabetes and cancer biotechnology firm called VivoRx Inc. This led to the founding in 1997 of APP Pharmaceuticals, of which he held 80% of the outstanding stock, and which was ultimately sold to Fresenius SE for $4.6 billion in July 2008.<ref name="app">{{cite news |url=https://www.bloomberg.com/news/articles/2008-07-07/fresenius-agrees-to-buy-app-for-up-to-4-6-billion |archive-url=https://web.archive.org/web/20160827004201/https://www.bloomberg.com/news/articles/2008-07-07/fresenius-agrees-to-buy-app-for-up-to-4-6-billion |url-status=dead |archive-date=2016-08-27 | title = Fresenius Agrees to Buy APP for Up to $4.6 Billion | author1 = Angela Cullen | author2 = Eva von Schaper | publisher = Bloomberg News | date = 2008-07-07 | access-date = 2016-08-26}}</ref> Soon-Shiong purchased Fujisawa, which sold injectable generic drugs, in 1998. Soon-Shiong later founded Abraxis BioScience, with which he would develop Abraxane,<ref name=labusinessjournal/> which took an existing chemotherapy drug, paclitaxel, and wrapped it in protein that made it easier to deliver to tumors. He became rich after it was approved by regulators and entered the market.<ref name="Forb 2020/08/27">{{Cite magazine|last=Knapp|first=Alex|date=August 27, 2020|title=The Inside Story Of Biotech's Barnum And His Covid Cures|url=https://www.forbes.com/sites/alexknapp/2020/08/27/the-inside-story-of-biotechs-barnum-and-his-covid-cures/|access-date=2020-08-27|magazine=Forbes}}</ref> Abraxis was sold to Celgene in 2010 in a cash-and-stock deal valued at just $2.9 billion, earning Soon-Shiong about $533 million in profits.<ref name="celgene">{{cite news |url = https://www.labusinessjournal.com/news/2010/oct/18/celgene-closes-abraxis-acquisition/|title = Celgene Closes Abraxis Acquisition|last = Crowe|first = Deborah|publisher = Los Angeles Business Journal|date = 18 October 2010|access-date = 20 October 2010}}{{Subscription required}}</ref>
Soon-Shiong founded NantHealth in 2007 to provide fiber-optic, cloud-based data infrastructure to share healthcare information.<ref>{{cite web|url=http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=222554189|archive-url=https://archive.today/20130407211439/http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=222554189|url-status=dead|archive-date=April 7, 2013|title=Company Overview of NantHealth, LLC|publisher=Bloomberg Businessweek|date=27 February 2013|access-date=27 February 2013}}</ref> Soon-Shiong went on to found NantWorks in September 2011, whose mission was "to converge ultra-low power semiconductor technology, supercomputing, high performance, secure advanced networks and augmented intelligence to transform how we work, play, and live."<ref>{{cite web| author=Shawn Baldwin| author-link=Shawn Baldwin|url=http://www.fastcompany.com/3006413/innovation-agents/shawn-baldwin-analyzes-patrick-soon-shiongs-value-creation-through-medicin |title=Dr. Patrick Soon Shiong Generates Billions of Value Creation in Medicine |work=Fast Company|date=September 20, 2014}}</ref><ref>{{cite news|title='Soon-Shiong's big rollup gets a name: NantWorks' |url=http://mobihealthnews.com/13083/soon-shiongs-big-rollup-gets-a-name-nantworks |first=Brian |last=Dolan|date=Sep 8, 2011 |access-date=24 January 2012}}</ref> It owns a number of technology companies in the fields of healthcare, commerce, digital entertainment as well as a venture capital firm in the healthcare, education, science, and technology sectors. Particular technologies include machine vision, object and voice recognition, low power semiconductors, supercomputing, and networking technologies.<ref name=bloomberg>{{cite web | url=https://www.bloomberg.com/profile/company/0203805D:US | title=NantWorks LLC – Company Profile and News | website=Bloomberg News }}</ref> In January 2013, he founded another biotech company, NantOmics, to develop cancer drugs based on protein kinase inhibitors. NantOmics and its sister company, NantHealth, were subsidiaries of NantWorks.<ref>{{cite journal | url=https://www.bloomberg.com/news/2013-01-28/cancer-researcher-turned-billionaire-starts-new-company.html | title=Cancer Researcher-Turned-Billionaire Starts New Company | author=Tirrell, Meg| journal = Bloomberg.com|date=2013-01-28 | access-date=2013-02-26|url-access=subscription}}</ref>
In 2013, Soon-Shiong became an early investor in Zoom, the video conferencing company.<ref>{{Cite web|title=Zoom Video Conferencing Adds $6.5M In Funding To Drive Expansion And Uptake In Education And Health|url=https://techcrunch.com/2013/09/24/zoom-video-conferencing-platform-adds-6-5m-in-funding-to-drive-expansion-and-uptake-in-education-and-health/|access-date=2021-10-08|website=TechCrunch|language=en-US|first=Darrell|last=Etherington|date=September 24, 2013}}</ref>
In September 2014, NantWorks LLC, a company headed by Soon-Shiong, invested $2.5 million in AccuRadio.<ref>{{Cite web|url=https://www.digitalmusicnews.com/2014/09/05/accuradio/|title=AccuRadio Gets $2.5 Million from Dr. Patrick Soon-Shiong...|date=2014-09-05|website=Digital Music News|language=en-US|access-date=2019-11-18}}</ref>
In 2015, Soon-Shiong's NantPharma purchased the drug Cynviloq from Sorrento Therapeutics for $90 million, including more than $1 billion in compensation for reaching regulatory and sales milestones.<ref>{{Cite web |last=Idrus |first=Amirah Al |date=2019-04-03 |title=Sorrento sues Soon-Shiong over 'catch-and-kill' of its cancer drug, a potential Abraxane rival |url=https://www.fiercebiotech.com/biotech/sorrento-sues-soon-shiong-over-catch-and-kill-its-cancer-drug-a-potential-abraxane-rival |access-date=2022-12-21 |website=Fierce Biotech }}</ref> Soon-Shiong did not push forward with FDA approval as the agreement dictated, and instead allowed critical patents and deadlines to lapse, presumably due to his financial interest in another drug that would compete with Cynviloq. This "catch and kill" method of eliminating competition follows a pattern of questionable business practices by Soon-Shiong,<ref>{{Cite web |last=Taylor |first=Nick Paul |date=2019-04-01 |title=Settlement set to sling Soon-Shiong out of biotech investment |url=https://www.fiercebiotech.com/biotech/settlement-set-to-sling-soon-shiong-out-biotech-investment |access-date=2022-12-21 |website=Fierce Biotech }}</ref> and claims of "looting" by the celebrity actress and musician Cher.<ref>{{Cite web |last=Adams |first=Ben |date=2017-06-27 |title=Despite 'looting' claims, Soon-Shiong's NantCell to buy Altor |url=https://www.fiercebiotech.com/biotech/despite-legal-claims-looting-soon-shiong-s-nantcell-set-to-buy-altor |access-date=2022-12-21 |website=Fierce Biotech }}</ref><ref>{{Cite web |last=Tahir |first=Darius |title=Cher escalates legal feud with Soon-Shiong |url=https://www.politico.com/story/2018/01/09/cher-escalates-legal-feud-with-soon-shiong-328615 |access-date=2022-12-21 |website=POLITICO |date=January 9, 2018 }}</ref>
In 2015, NantWorks LLC invested in Wibbitz in their $8 million series B funding.<ref>{{Cite web|url=https://www.alleywatch.com/2015/06/wibbitz-raises-8m-to-create-all-the-news-that-is-fit-to-automate/|title=Wibbitz Raises $8M to Create All the News that Is Fit to Automate|date=2015-06-03|website=AlleyWatch|language=en-US|access-date=2019-11-18}}</ref> In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion.<ref name="Wall Street Journal">{{cite journal | author = Driebusch, Corrie | date = 2015-07-28 | title = NantKwest Gives Biotech Another Big IPO| journal = The Wall Street Journal | url=https://www.wsj.com/articles/nantkwest-shares-pop-in-first-day-trading-1438096121 | access-date=2016-11-21 }}</ref> In April 2016, the ''Los Angeles Times'' reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 million, making him one of the highest paid CEOs.<ref name = latimes2>{{cite journal | author = Petersen, Melody | date = 2016-04-27 | title = L.A. Billionaire Soon-Shiong Gets $148-Million Payday Even as His Firm's Stock Tanks | journal = Los Angeles Times | format = online | url = https://www.latimes.com/business/la-fi-0428-soon-shiong-ceo-pay-20160428-story.html | access-date = 2016-11-20 }}</ref> Soon-Shiong is also a member of the Berggruen Institute's 21st Century Council.<ref>{{cite web|title=Berggruen Institute|url=http://governance.berggruen.org/councils/21st-century-council/members|access-date=2017-01-07|archive-url=https://web.archive.org/web/20170106173236/http://governance.berggruen.org/councils/21st-century-council/members|archive-date=2017-01-06|url-status=dead}}</ref><ref>Palmeri, Christopher. [https://www.bloomberg.com/news/articles/2016-05-04/-homeless-billionaire-gets-l-a-welcome-after-500-million-gift "'Homeless Billionaire' Charms L.A. With $500 Million Gift"], Bloomberg News, May 4, 2016</ref>
In September 2018, his company NantEnergy announced the development of a zinc–air battery with a projected cost of $100 per kilowatt-hour, which is less than one-third the cost of lithium-ion batteries.<ref>{{Cite news|url=https://www.nytimes.com/2018/09/26/business/energy-environment/zinc-battery-explain.html|title=How Zinc Batteries Could Change Energy Storage|work=The New York Times |date=September 26, 2018 |access-date=2018-10-03 |last1=Penn |first1=Ivan }}</ref>
In 2019, Soon-Shiong became an investor in Directa Plus, a European-based graphene-based technology company, where he owns 28 percent of the company.<ref>{{Cite web|date=2019-10-25|title=Biotech billionaire Patrick Soon-Shiong raises stake in graphene maker Directa Plus|url=https://www.proactiveinvestors.com/companies/news/905644/biotech-billionaire-patrick-soon-shiong-raises-stake-in-graphene-maker-directa-plus-905644.html|access-date=2021-10-08|website=Proactiveinvestors NA}}</ref>
In early 2021, Soon-Shiong merged publicly traded NantKwest (NASDAQ: NK) with privately held ImmunityBio (formerly NantCell).<ref>{{Cite web|date=2021-03-09|title=ImmunityBio and NantKwest Complete Merger|url=https://immunitybio.com/immunitybio-and-nantkwest-complete-merger/|access-date=2021-10-08|website=ImmunityBio|language=en-US}}</ref> The new public entity after the merger is known as ImmunityBio, Inc., trading on NASDAQ under the ticker symbol IBRX.
In 2021, Soon-Shiong announced a new investment of $29 million in a biorenewables company called NantRenewables at SeaPoint in Savannah, Georgia.<ref>{{cite web |url =https://gov.georgia.gov/press-releases/2021-09-08/gov-kemp-announces-bioplastics-company-open-facility-savannah-creating |title = Gov. Kemp Announces Bioplastics Company to Open Facility in Savannah, Creating Over 100 Jobs| date=September 8, 2021 }}</ref><ref>{{cite web |url=http://middlegeorgiaceo.com/news/2021/09/nantrenewables-build-new-bioplastics-manufacturing-plant-seapoint-industrial-terminal-complex-savannah-2/ |title = NANTRenewables to Build New Bioplastics Manufacturing Plant at SeaPoint Industrial Terminal Complex in Savannah }}</ref> In January 2022, Soon-Shiong opened a new manufacturing facility and campus in Cape Town, South Africa with President Ramaphosa.<ref>{{Cite news|last=Roelf|first=Wendell|date=2022-01-19|title=Billionaire Soon-Shiong opens new vaccine plant in South Africa|work=Reuters|url=https://www.reuters.com/world/africa/billionaire-soon-shiong-opens-new-vaccine-plant-south-africa-2022-01-19/|access-date=2022-02-19}}</ref> Soon-Shiong and his entities are reported to be investing over 4 billion RAND (~$250 million) into the continent.<ref>{{Cite web|last=Venter|first=Irma|title=Ramaphosa, billionaire Soon-Shiong open NantSA vaccine production campus in Cape Town|url=https://www.engineeringnews.co.za/article/ramaphosa-billionaire-soon-shiong-open-nantsa-vaccine-production-campus-in-cape-town-2022-01-19|access-date=2022-02-19|website=www.engineeringnews.co.za}}</ref> In February, Soon-Shiong invested in Sienza, a lithium battery company in Pasadena, California.<ref>{{Cite web|date=Feb 18, 2022|title=Sienza Energy Snags Series A For Battery Technology|url=https://www.socaltech.com/sienza_energy_snags_series_a_for_battery_technology/s-0082207.html}}</ref>
===Ownership of the ''Los Angeles Times''=== {{Further|News media endorsements in the 2024 United States presidential election#Suppression of Harris endorsements}} In February 2018, Soon-Shiong's investment firm NantCapital reached a deal to purchase ''Los Angeles Times'' and ''The San Diego Union-Tribune'' from Tronc Inc. for "nearly $500 million in cash" as well as the assumption of $90 million in pension obligations.<ref>{{cite news|url=https://www.latimes.com/business/hollywood/la-fi-ct-los-angeles-times-sold-20180207-story.html|title=Billionaire Patrick Soon-Shiong reaches deal to buy L.A. Times, San Diego Union-Tribune|date=February 7, 2018 |access-date=February 7, 2018}}</ref> Soon-Shiong, with this acquisition, became one of the first Asian-Americans to be a media proprietor through ownership in a major daily newspaper in the United States.<ref>{{Cite web|url=http://www.journal-isms.com/2018/02/l-a-times-sold-to-asian-american-billionaire/|archive-url=https://web.archive.org/web/20180210011239/http://journal-isms.com/2018/02/l-a-times-sold-to-asian-american-billionaire/|url-status=dead|archive-date=February 10, 2018|title=L.A. Times Sold to Asian American Billionaire|date=February 7, 2018}}</ref> The sale closed on June 18, 2018.<ref name="Tronc" />
In 2020, Soon-Shiong blocked the editorial board from making any endorsement in the Democratic presidential primaries, overruling its intended endorsement of Elizabeth Warren; the paper did endorse Biden in the general election.<ref name=Semafor/>
During Soon-Shiong's ownership of the ''Los Angeles Times'', his daughter, Nika Soon-Shiong, became interested in the newspaper and sought to influence coverage, in both the newsroom and opinion pages.<ref name=2022Daughter>Daniel Lippman, Christopher Cadelago and Max Tani, [https://www.politico.com/news/2022/09/18/la-times-tension-patrick-soon-shiong-00056601 Tensions rise between the LA Times and its billionaire owner], ''Los Angeles Times'' (September 18, 2022).</ref> Many ''Times'' staffers expressed alarm at the younger Soon-Shiong's activity, which they viewed as meddling, including privately and publicly contacting staffers to advocate her views.<ref name=2022Daughter/>
In July 2023, Soon-Shiong sold the ''San Diego Union-Tribune'' to MediaNews Group.<ref>{{Cite web |last= |date=2023-07-10 |title=LA Times sells San Diego Union-Tribune to MediaNews Group affiliate |url=https://www.kpbs.org/news/local/2023/07/10/la-times-sells-san-diego-union-tribune-to-medianews-group-affiliate |access-date=2023-07-10 |website=KPBS Public Media }}</ref><ref>{{Cite web |date=2023-07-10 |title=LA billionaire sells San Diego Union-Tribune to owner of Southern California News Group |url=https://www.ocregister.com/2023/07/10/la-billionaire-sells-san-diego-union-tribune-to-owner-of-southern-california-news-group/ |access-date=2023-07-10 |website=Orange County Register |language=en-US}}</ref>
In October 2024, as the ''Los Angeles Times'' editorial board was preparing to endorse Kamala Harris in the 2024 United States presidential election, Soon-Shiong blocked the newspaper from making any endorsement.<ref name=Semafor>{{Cite web|author=Max Tani|title=Los Angeles Times won't endorse for president |url=https://www.semafor.com/article/10/22/2024/los-angeles-times-wont-endorse-for-president |date=October 22, 2024|website=Semafor }}</ref><ref name=Beckett2024>{{Cite web|title=Los Angeles Times sees resignations and loss of subscriptions after owner blocks Harris endorsement|author=Lois Beckett|newspaper=Los Angeles Times|date=October 25, 2024|url=https://www.theguardian.com/us-news/2024/oct/25/los-angeles-times-owner-blocks-harris-endorsement}}</ref> This was the first time since 2004 that the newspaper had not endorsed a presidential candidate.<ref name=Semafor/> In response to Soon-Shiong's decision to block the Harris endorsement, there was a wave of subscription cancellations, staff anger, and several members of the paper's editorial board resigned in protest including editorials editor Mariel Garza and two editorial writers, Pulitzer Prize winner Robert Greene and Karin Klein.<ref name=Beckett2024/><ref>{{Cite web |last=Chan |first=Sewell |title=Los Angeles Times editorials editor resigns after owner blocks presidential endorsement |url=https://www.cjr.org/business_of_news/los-angeles-times-editorials-editor-resigns-after-owner-blocks-presidential-endorsement.php |date=October 23, 2024 |website=Columbia Journalism Review }}</ref> Harry Litman, a senior legal affairs columnist for the Times’ opinion page, also resigned stating, "My resignation is a protest and visceral reaction against the conduct of the paper’s owner, Dr. Patrick Soon-Shiong."<ref name=guard/> Nearly 2,000 subscribers to the paper unsubscribed in the wake of the decision.<ref name=Beckett2024/> A day later, ''TheWrap'' reported that the Los Angeles Times editorial board had planned a series of articles tentatively titled "The Case Against Trump" which was killed by Soon-Shiong.<ref>{{Cite web |last=Lincoln |first=Ross A. |date=2024-10-25 |title=Exclusive: LA Times Planned 'Case Against Trump' Series Alongside Kamala Harris Endorsement Before Owner Quashed It|url=https://www.thewrap.com/la-times-case-against-trump-kamala-endorsement-canceled/ |access-date=2024-10-25 |website=TheWrap |language=en-US}}</ref><ref>{{cite news|url=https://www.theguardian.com/media/2024/oct/25/patrick-soon-shiong-the-billionaire-la-times-owner-who-blocked-harris-endorsement|title=Patrick Soon-Shiong: the billionaire LA Times owner who blocked Harris endorsement|work=The Guardian|date=October 25, 2024 |last1=Milmo |first1=Dan |last2=Beckett |first2=Lois }}</ref>
In November 2024, the ''Los Angeles Times'' fired its entire editorial board, and Soon-Shiong announced plans to replace them with a new team. Soon-Shiong defended the restructuring for a "fair and balanced newspaper,” echoing the Fox News slogan. Soon-Shiong further promised a "rebirth" for the newspaper, adding "Every American’s views should be heard."<ref>{{Cite web |last=Burch |first=Sean |date=November 15, 2024 |title=LA Times Owner Promises Newsroom 'Rebirth' Where 'All Voices' Are Heard |url=https://www.thewrap.com/los-angeles-times-owner-patrick-soon-shiong-newsroom-rebirth/ |website=TheWrap}}</ref><ref>{{Cite web |last=Patten |first=Dominic |date=November 11, 2024 |title="Fair & Balanced": Trump 2.0 Era Brings New Los Angeles Times Editorial Board, Owner Promises With Fox News Motto Echo |url=https://deadline.com/2024/11/trump-la-times-editorial-board-1236173370/ |website=Deadline Hollywood}}</ref>
In December 2024, Soon-Shiong announced that the ''Los Angeles Times'' would employ an AI-powered bias meter into the newspaper's coverage. The announcement came after Soon-Shiong expressed his desire to include more conservative voices in the paper's opinion section, following Donald Trump's victory in the 2024 presidential election.<ref name=guard>{{cite web |title=Owner of Los Angeles Times says paper will employ AI-powered 'bias meter' |url=https://www.theguardian.com/media/2024/dec/06/la-times-ai-bias-meter-owner?utm_source=dlvr.it&utm_medium=bluesky&CMP=bsky_gu |date=December 6, 2024 |first=Anna |last=Betts |website=The Guardian}}</ref><ref>{{cite web |title=LA Times owner plans to add AI-powered 'bias meter' on news stories, sparking newsroom backlash |url=https://www.cnn.com/2024/12/05/media/la-times-soon-shiong-ai-bias-meter-opinion/index.html |date=December 5, 2024 |first1=Liam |last1=Reilly |first2=Jon |last2=Passantino |website=CNN}}</ref><ref>{{cite web |title=LA Times owner adding AI 'bias meter' to articles |url=https://thehill.com/homenews/media/5026257-patrick-soon-shiong-bias-meter/amp/ |date=December 6, 2024 |first=Dominick |last=Mastrangelo |website=The Hill}}</ref>
In January 2025, Soon-Shiong was accused of diverting the meaning of a ''Los Angeles Times'' op-ed which opposed the confirmation of Robert F. Kennedy Jr. as Health and Human Services Secretary. Soon-Shiong had previously endorsed Kennedy Jr. for the role. The op-ed's author, Eric Reinhart, said that portions of his piece which explicitly called against the confirmation were cut out without his approval, shortly before publication.<ref name="howard-31jan2025">{{cite news |last1=Howard |first1=Andrew |title=LA Times accused by writer of 'distorting' an op-ed – in a way that aligns with owner's pro-RFK views |url=https://www.politico.com/news/2025/01/31/la-times-rfk-jr-opinion-patrick-soon-shiong-010210 |access-date=1 February 2025 |work=Politico |date=31 January 2025 |language=en}}</ref> One of the removed excerpts argued that Kennedy Jr. would "inflict preventable death on [millions of Americans]" due to his "egomaniacal disregard for scientific evidence".<ref name="quinlan-31jan2025">{{cite magazine |last1=Quinlan Houghtaling |first1=Ellie |title=Why Did the LA Times Edit This RFK Jr. Article to Be More Pro-Trump? |url=https://newrepublic.com/post/191007/la-times-robert-f-kennedy-jr-donald-trump |access-date=1 February 2025 |magazine=The New Republic |date=31 January 2025}}</ref> The op-ed was published under the headline "Trump’s healthcare disruption could pay off — if he pushes real reform". In contrast, Reinhart's suggested title was "RFK Jr’s Wrecking Ball Won’t Fix Public Health". When the op-ed was published, Soon-Shiong shared it on X along with a comment saying that Kennedy Jr. was "our best chance of [pushing reform in the American healthcare system]".<ref name="howard-31jan2025" />
In October 2025, Soon-Shiong joined The Megyn Kelly Show to discuss the ''Los Angeles Times''<nowiki/>' refusal to publish an endorsement of Kamala Harris during the 2024 presidential election.<ref>{{Cite web |date=2025-10-10 |title=Why the Owner of the LA Times Killed the Kamala Endorsement and Decided to Take the Paper Public |url=https://www.latimes.com/zqb2hfi9hxs-123 |access-date=2025-10-17 |website=Los Angeles Times |language=en-US}}</ref> He also discussed taking the ''Times'' public and other media trends.<ref>{{Cite web |last=Bryant |first=Jacob |date=2025-10-09 |title=LA Times Owner Patrick Soon-Shiong Denies 'Billionaires Club' With Jeff Bezos Squandered Kamala Harris' Campaign {{!}} Video |url=https://www.thewrap.com/patrick-soon-shiong-denies-billionaires-club-squandered-harris-campaign/ |access-date=2025-10-17 |website=TheWrap |language=en-US}}</ref>
== Philanthropy == A 2017 Politico report found that Soon-Shiong's research foundation, the Chan Soon-Shiong NantHealth Foundation, which he named after his wife, had spent over 70% on businesses and non-profit organizations he controlled. Furthermore, it found that most of its grants were awarded to organizations that did business with Soon-Shiong's companies. The Foundation also paid some employees from Soon-Shiong's companies, which is a potentially inappropriate use of charitable funds to cover unrelated business overhead.<ref name=":1" />
The foundation contributed a quarter of a $12 million donation by Soon-Shiong-controlled organizations to the University of Utah to set up a gene mapping project. Control over the grant specifications was given over to Soon-Shiong's donating organizations, and his NantHealth company was awarded the $10 million contract.<ref name=":1" /> A subsequent audit report by the Utah government found that the university had failed to follow the state's procurement laws requiring a competitive bidding process for public institutions.<ref name=":2">{{Cite news |last=Wood |first=Benjamin |date=October 17, 2017 |title=Hughes questions whether University of Utah had a 'Cinderella-slippered' deal when it directed donation money back to donor's company |url=https://www.sltrib.com/news/education/2017/10/17/audit-university-of-utah-violated-state-law-by-directing-donation-money-back-to-donors-company/ |access-date=October 24, 2024 |work=The Salt Lake Tribune}}</ref> Utah House Speaker Greg Hughes described the audit as showing that the deal was "trying to Cinderella-slipper something for one person, or for one entity".<ref>{{Cite news |last=Robbins |first=Rebeca |date=October 19, 2017 |title=Utah audit finds legal violations in university's deal with Patrick Soon-Shiong |url=https://www.statnews.com/2017/10/19/soon-shiong-utah-audit/ |access-date=October 24, 2024 |work=STAT}}</ref> The university accepted the results of the audit and said that its recommended changes would be made.<ref name=":2" />
The family foundation has partnered with the Clinton Foundation.<ref name=":1" /> In 2023, he was recognized as one of the 100 most influential celebrities in oncology by OncoDaily.<ref>{{Cite web |date= |title=100 Influential Celebrities in Oncology: The 2023 Edition |url=https://oncodaily.com/positive/28416 |url-status=live |archive-url= |access-date= |website=www.oncodaily.com}}</ref>
== Politics == Soon-Shiong and his family were major donors to the Hillary Clinton 2016 presidential campaign.<ref name=":1" /> According to ''Politico'', Soon-Shiong twice met privately with Donald Trump during his 2016–2017 presidential transition in an unsuccessful attempt to obtain a position in the administration.<ref name=":1" /><!-- and then what? -->
== Personal life == Soon-Shiong is married to former actress Michele B. Chan.<ref>{{Cite web |title=Alumni stories – Wits University |url=https://www.wits.ac.za/alumni/history-and-traditions/your-wits-story/alumni-stories/ |access-date=2024-06-21 |website=www.wits.ac.za}}</ref> They have two children, including Nika Soon-Shiong, and live in Los Angeles.<ref name="ForbesProfile">{{Cite journal |author=Forbes Staff |title=Forbes profile: Patrick Soon-Shiong |url=https://www.forbes.com/profile/patrick-soon-shiong/ |access-date=27 November 2019 |website=Forbes.com}}</ref> He has committed to the Giving Pledge and has pledged to give away at least half of his wealth to philanthropy.<ref name="familyfoundation">{{cite web |title=Chan Soon-Shiong Family Foundation |url=https://fconline.foundationcenter.org/fdo-grantmaker-profile?key=CHAN153 |work=Foundation Directory Online}}</ref>
== Notes == {{Reflist|group=Note}}
== References == {{Reflist}}
{{Authority control}}
{{DEFAULTSORT:Soon-Shiong, Patrick}} Category:1952 births Category:Living people Category:20th-century American businesspeople Category:20th-century American inventors Category:20th-century South African businesspeople Category:20th-century South African medical doctors Category:21st-century American businesspeople Category:21st-century American inventors Category:21st-century American philanthropists Category:21st-century American medical doctors Category:21st-century American scientists Category:21st-century South African businesspeople Category:21st-century South African medical doctors Category:American billionaires Category:American chief executives in the health care industry Category:American investors Category:American medical academics Category:American medical researchers Category:American newspaper publishers (people) Category:American people of Chinese descent Category:American philanthropists Category:American transplant surgeons Category:Benjamin Franklin Medal (Franklin Institute) laureates Category:Businesspeople from Los Angeles Category:Businesspeople in information technology Category:Businesspeople in the pharmaceutical industry Category:David Geffen School of Medicine at UCLA faculty Category:Hakka scientists Category:Inventors from California Category:Los Angeles Lakers owners Category:Los Angeles Times people Category:People from Gqeberha Category:Naturalized citizens of the United States Category:Medical doctors from Los Angeles Category:South African academics Category:South African billionaires Category:South African chief executives Category:South African emigrants to the United States Category:South African inventors Category:South African investors Category:South African medical researchers Category:South African people of Chinese descent Category:South African philanthropists Category:South African publishers (people) Category:South African transplant surgeons Category:University of British Columbia alumni Category:21st-century surgeons Category:20th-century American surgeons